Evaluation of Pulsed Field Ablation of the Posterior Nasal Nerve for Chronic Rhinitis

NCT06598319 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-30

No results posted yet for this study

Summary

Evaluation of safety, effectiveness and tolerability of the Aventix Medical Device used for the treatment of chronic rhinitis

Conditions

  • Chronic Rhinitis

Interventions

DEVICE

NOVOCLEAR™ Device

Pulsed field energy applied to soft tissues in the nasal airway, including the posterior nasal nerve distribution.

Sponsors & Collaborators

  • Aventix Medical Inc.

    lead INDUSTRY

Principal Investigators

  • Raymond Weiss, MD · Bay Area ENT

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-15
Primary Completion
2026-04-30
Completion
2026-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06598319 on ClinicalTrials.gov